|
| Lymph node metastases resisted T cell-mediated cytotoxicity, induced antigen-specific regulatory T cells, and generated tumor-specific immune tolerance that subsequently facilitated distant tumor colonization.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that antigen-presenting cancer-associated fibroblasts directly ligated and induced naive CD4+ T cells into regulatory T cells in an antigen-specific manner.
[Cancer Cell] |
|
|
|
| Researchers showed that outer membrane vesicles fused to a tumor antigen and produced in the intestine by ingested genetically engineered bacteria function as effective tumor vaccines in mice.
[Nature Biomedical Engineering] |
|
|
|
| Investigators designed an albumin nanoparticle, Nano-PI, containing the immunomodulators PI3Kγ inhibitor and paclitaxell and treated two breast cancer mouse models with Nano-PI in combination with α-PD1, which remodeled the tumor microenvironment in both lymph nodes and tumors.
[Science Translational Medicine] |
|
|
|
| Scientists reported a T cell–intrinsic role for Mincle in the pathogenesis of experimental autoimmune encephalomyelitis.
[Nature Communications] |
|
|
|
| The authors correlated high versican-V1 expression in multiple sclerosis (MS) lesions with deficient premyelinating oligodendrocytes, and highlighted its selective upregulation amongst chondroitin sulfate proteoglycans members in experimental autoimmune encephalomyelitis lesions modeling MS.
[Nature Communications] |
|
|
|
| Researchers revealed mechanisms of microbiota-mediated gut-bone crosstalk that were relevant to the immunological restraint of melanoma metastasis and tumor growth in bone.
[Journal of Clinical Investigation] |
|
|
|
| Using an established mouse model of rheumatoid arthritis, scientists showed that chronic inflammatory arthritis resulted in rhythmic joint inflammation and drove major changes in muscle and liver energy metabolism and rhythmic gene expression.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers provided evidence that the interleukin 23 (IL23) receptor expressed by tumor-infiltrating regulatory T cells promoted suppressive activity.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators showed that vasoactive intestinal peptide (VIP), produced by the nervous system in response to feeding, potentiated the production of effector cytokines by intestinal type 2 and type 3 innate lymphoid cells.
[Mucosal Immunology] |
|
|
|
| Scientists investigated the prognostic heterogeneity of regulatory T cells in colorectal cancer (CRC) by co-expression patterns and spatial analyses with diverse T cell markers, using multiplex fluorescence immunohistochemistry and digital image analysis in two consecutive series of primary CRCs.
[Modern Pathology] |
|
|
|
| Researchers highlighted the importance of regulated phosphorylation of c-MYC (MYC) at Threonine 58 and Serine 62 for T cell transformation.
[Molecular Cancer Research] |
|
|
|
| The authors queried the expression of transglutaminase genes and examined whether they play a role in heart-associated immune responses.
[Scientific Reports] |
|
|
|
|
| Investigators describe the basic tenets of predator-prey theory as applied to ‘predation’ by immune cells and the ‘extinction’ of cancer cells.
[Nature Reviews Immunology] |
|
|
|
| Scientists discuss the contribution of mechanical factors triggering an exaggerated inflammatory response, the impact of adipose tissue and altered lipid metabolism and the influence of intestinal dysbiosis in the psoriatic arthritis disease process.
[Nature Reviews Rheumatology] |
|
|
|
| The authors discuss the cellular, as well as the soluble and surface-bound signals that regulate CD8+ T cell phenotypes and functions in a topologically-regulated manner, highlighting where new spatial transcriptomics and imaging technologies can uncover mechanistic insights.
[Trends in Cancer] |
|
|
|
|
| Boehringer Ingelheim and OSE Immunotherapeutics SA announced a new step in their collaboration under which Boehringer Ingelheim obtained exclusive rights to BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/ CD47 myeloid pathway being evaluated in patients with hepatocellular carcinoma.
[OSE Immunotherapeutics SA] |
|
|
|
| Immunic, Inc. announced the start of the patient cohorts in its ongoing Phase I clinical trial of IMU-856, the company’s third clinical asset, in patients with celiac disease.
[Immunic, Inc.] |
|
|
|
|
|
|
|
| | Cancer Research Center of Lyon – Lyon, France |
|
|
|
| | The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
| | New York University College of Dentistry – New York, New York, United States |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
